PriceTargets.com logo

Monopar Therapeutics - MNPR Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $106.20
  • Forecasted Upside: 33.64%
  • Number of Analysts: 13
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 10 Buy Ratings
  • 2 Strong Buy Ratings
$79.47 As of 12/4/2025 05:00 PM ET
▲ +2.29 (2.97%)

This chart shows the closing price for MNPR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Monopar Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MNPR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MNPR

Analyst Price Target is $106.20
▲ +33.64% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Monopar Therapeutics in the last 3 months. The average price target is $106.20, with a high forecast of $125.00 and a low forecast of $74.00. The average price target represents a 33.64% upside from the last price of $79.47.

This chart shows the closing price for MNPR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 13 polled investment analysts is to buy stock in Monopar Therapeutics. This rating has held steady since October 2025, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 2 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 2 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 2 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/14/2025Raymond James FinancialDowngradeStrong-Buy ➝ Outperform$142.00 ➝ $123.00
11/10/2025Leerink PartnrsUpgradeStrong-Buy
11/10/2025Leerink PartnersInitiated CoverageOutperform$115.00
11/9/2025Chardan CapitalBoost TargetBuy ➝ Buy$85.00 ➝ $100.00
10/13/2025BarclaysSet TargetOverweight$125.00
10/13/2025BarclaysInitiated CoverageOverweight$125.00
10/10/2025Jones TradingUpgradeHold ➝ Strong-Buy
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/6/2025Raymond James FinancialSet TargetStrong-Buy ➝ Strong-Buy$80.00 ➝ $142.00
10/2/2025OppenheimerSet TargetOutperform ➝ Outperform$77.00 ➝ $115.00
9/29/2025HC WainwrightSet TargetBuy ➝ Buy$70.00 ➝ $105.00
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/25/2025Piper SandlerSet TargetOverweight ➝ Overweight$76.00 ➝ $95.00
9/25/2025Chardan CapitalBoost TargetBuy ➝ Buy$60.00 ➝ $85.00
9/25/2025BTIG ResearchBoost TargetBuy ➝ Buy$87.00 ➝ $104.00
9/24/2025Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight
9/23/2025Lake Street CapitalInitiated CoverageBuy$106.00
9/23/2025Lake Street CapitalInitiated CoverageBuy$106.00
9/16/2025Chardan CapitalReiterated RatingBuy ➝ Buy$60.00
9/15/2025BTIG ResearchReiterated RatingBuy ➝ Buy$87.00
9/9/2025BTIG ResearchInitiated CoverageBuy$87.00
9/3/2025OppenheimerInitiated CoverageOutperform$77.00
9/2/2025Raymond James FinancialInitiated CoverageStrong-Buy$80.00
8/27/2025Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$74.00
8/26/2025HC WainwrightInitiated CoverageBuy$70.00
8/13/2025Chardan CapitalReiterated RatingBuy ➝ Buy$60.00
7/7/2025Cantor FitzgeraldInitiated CoverageOverweight$74.00
6/23/2025Chardan CapitalInitiated CoverageBuy$60.00
4/2/2025Jones TradingReiterated RatingBuy ➝ Hold
4/1/2025HC WainwrightReiterated RatingBuy ➝ Buy$40.00 ➝ $40.00
3/19/2025Piper SandlerReiterated RatingOverweight$76.00
1/22/2025HC WainwrightBoost TargetBuy ➝ Buy$22.00 ➝ $40.00
1/10/2025Piper SandlerInitiated CoverageOverweight$72.00
11/11/2024HC WainwrightBoost TargetBuy ➝ Buy$6.00 ➝ $22.00
10/11/2024Rodman & RenshawInitiated CoverageBuy$50.00
8/14/2024HC WainwrightBoost TargetBuy ➝ Buy$2.00 ➝ $6.00
5/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00
4/11/2024JonestradingUpgradeHold ➝ Buy$10.00
5/15/2023HC WainwrightLower Target$30.00 ➝ $10.00
3/29/2023Maxim GroupDowngradeBuy ➝ Hold
3/24/2023EF Hutton Acquisition Co. IReiterated RatingBuy$120.00
2/15/2023HC WainwrightReiterated RatingBuy$30.00
2/14/2023EF Hutton Acquisition Co. IReiterated RatingBuy$120.00
1/23/2023EF Hutton Acquisition Co. IInitiated CoverageBuy$120.00
12/9/2022Roth CapitalReiterated RatingBuy
11/16/2022Maxim GroupBoost Target$40.00
10/3/2022Brookline Capital ManagementReiterated RatingBuy
8/16/2022HC WainwrightLower TargetBuy$45.00 ➝ $30.00
3/25/2022HC WainwrightReiterated RatingBuy$45.00
3/24/2022Roth CapitalReiterated RatingBuy
11/1/2021HC WainwrightInitiated CoverageBuy$45.00
5/25/2021Brookline Capital ManagementReiterated RatingBuy
1/28/2021Roth CapitalInitiated CoverageBuy$245.00
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.55 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2025
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2025
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2025
  • 6 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2025
  • 10 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2025
  • 11 very positive mentions
  • 21 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 4 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/5/2025
  • 8 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/5/2025

Current Sentiment

  • 8 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Monopar Therapeutics logo
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Read More

Today's Range

Now: $79.47
Low: $75.47
High: $79.90

50 Day Range

MA: $85.23
Low: $75.90
High: $102.05

52 Week Range

Now: $79.47
Low: $20.16
High: $105.00

Volume

155,064 shs

Average Volume

168,105 shs

Market Capitalization

$530.86 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.46

Frequently Asked Questions

What sell-side analysts currently cover shares of Monopar Therapeutics?

The following equities research analysts have issued research reports on Monopar Therapeutics in the last year: Barclays PLC, BTIG Research, Cantor Fitzgerald, Chardan Capital, HC Wainwright, Jones Trading, Lake Street Capital, Leerink Partners, Leerink Partnrs, Oppenheimer Holdings, Inc., Piper Sandler, Raymond James Financial, Inc., Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for MNPR.

What is the current price target for Monopar Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Monopar Therapeutics in the last year. Their average twelve-month price target is $106.20, suggesting a possible upside of 33.6%. Barclays PLC has the highest price target set, predicting MNPR will reach $125.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $74.00 for Monopar Therapeutics in the next year.
View the latest price targets for MNPR.

What is the current consensus analyst rating for Monopar Therapeutics?

Monopar Therapeutics currently has 1 sell rating, 10 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MNPR will outperform the market and that investors should add to their positions of Monopar Therapeutics.
View the latest ratings for MNPR.

What other companies compete with Monopar Therapeutics?

Other companies that are similar to Monopar Therapeutics include Mesoblast, Aurinia Pharmaceuticals, Avadel Pharmaceuticals, Harmony Biosciences and Sarepta Therapeutics. Learn More about companies similar to Monopar Therapeutics.

How do I contact Monopar Therapeutics' investor relations team?

Monopar Therapeutics' physical mailing address is 1000 SKOKIE BLVD SUITE 350, WILMETTE IL, 60091. The company's listed phone number is 847-388-0349 and its investor relations email address is [email protected]. The official website for Monopar Therapeutics is www.monopartx.com. Learn More about contacing Monopar Therapeutics investor relations.